Tau clearance mechanisms and their possible role in the pathogenesis of Alzheimer disease

Frontiers in Neurology

Volumn 4 SEP, Issue , 2013, Pages

  Chesser, Adrianne S ^a   Pritchard, Susanne M ^a   Johnson, Gail V W ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Autophagy; Degradation; Proteasome; Proteolysis; Tau

Indexed keywords

AMINOPEPTIDASE; CALPAIN; CASPASE 3; CASPASE 6; HUNTINGTIN; PROTEASOME; TAU PROTEIN; THROMBIN;

ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; CLEARANCE; ENZYME ACTIVITY; HUMAN; IMMUNOREACTIVITY; MICROARRAY ANALYSIS; NONHUMAN; PATHOGENESIS; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TAUOPATHY; UBIQUITINATION;

EID: 84885352675     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2013.00122     Document Type: Review

References (108)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 82:239-59. doi:10.1007/BF00308809.
2. Arnold CS, Johnson GV, Cole RN, Dong DL, Lee M, Hart GW. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem (1996) 271:28741-4. doi:10.1074/jbc.271.46.28741.
3. Reynolds MR, Berry RW, Binder LI. Nitration in neurodegeneration: deciphering the "Hows" "nYs." Biochemistry (2007) 46:7325-36. doi:10.1021/bi700430y.
4. Cohen TJ, Guo JL, Hurtado DE, Kwong LK, Mills IP, Trojanowski JQ, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun (2011) 2:252. doi:10.1038/ncomms1255.
5. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, Jackson GR, et al. Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 26:1946-59. doi:10.1096/fj.11-199851.
6. Ward SM, Himmelstein DS, Lancia JK, Binder LI. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans (2012) 40:667-71. doi:10.1042/BST20120134.
7. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, Van Eersel J, et al. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell (2010) 142:387-97. doi:10.1016/j.cell.2010.06.036.
8. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F, et al. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 31:700-11. doi:10.1523/JNEUROSCI.4152-10.2011.
9. Guillozet AL, Weintraub S, Mash DC, Mesulam MM. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol (2003) 60:729-36. doi:10.1001/archneur.60.5.729.
10. Karsten SL, Sang TK, Gehman LT, Chatterjee S, Liu J, Lawless GM, et al. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration. Neuron (2006) 51:549-60. doi:10.1016/j.neuron.2006.07.019.
11. Sengupta S, Horowitz PM, Karsten SL, Jackson GR, Geschwind DH, Fu Y, et al. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro. Biochemistry (2006) 45:15111-9. doi:10.1021/bi061830d.
12. Kudo LC, Parfenova L, Ren G, Vi N, Hui M, Ma Z, et al. Puromycin-sensitive aminopeptidase (PSA/NPEPPS) impedes development of neuropathology in hPSA/TAU(P301L) double-transgenic mice. Hum Mol Genet (2011) 20:1820-33. doi:10.1093/hmg/ddr065.
13. Olesen OF. Proteolytic degradation of microtubule associated protein tau by thrombin. Biochem Biophys Res Commun (1994) 201:716-21. doi:10.1006/bbrc.1994.1759.
14. Wang X, An S, Wu JM. Specific processing of native and phosphorylated tau protein by proteases. Biochem Biophys Res Commun (1996) 219:591-7. doi:10.1006/bbrc.1996.0278.
15. Khlistunova I, Biernat J, Wang Y, Pickhardt M, Von Bergen M, Gazova Z, et al. Inducible expression of tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem (2006) 281:1205-14. doi:10.1074/jbc. M507753200.
16. Tennstaedt A, Popsel S, Truebestein L, Hauske P, Brockmann A, Schmidt N, et al. Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates. J Biol Chem (2012) 287:20931-41. doi:10.1074/jbc. M111.316232.
17. Canu N, Dus L, Barbato C, Ciotti MT, Brancolini C, Rinaldi AM, et al. Tau cleavage and dephosphorylation in cerebellar granule neurons undergoing apoptosis. J Neurosci (1998) 18:7061-74.
18. Xie HQ, Johnson GV. Calcineurin inhibition prevents calpain-mediated proteolysis of tau in differentiated PC12 cells. J Neurosci Res (1998) 53:153-64. doi:10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5.
19. Garg S, Timm T, Mandelkow EM, Mandelkow E, Wang Y. Cleavage of tau by calpain in Alzheimer's disease: the quest for the toxic 17 kD fragment. Neurobiol Aging (2011) 32:1-14. doi:10.1016/j.neurobiolaging.2010.09.008.
20. Liu MC, Kobeissy F, Zheng W, Zhang Z, Hayes RL, Wang KK. Dual vulnerability of tau to calpains and caspase-3 proteolysis under neurotoxic and neurodegenerative conditions. ASN Neuro (2011) 3:e00051. doi:10.1042/AN20100012.
21. Fasulo L, Ugolini G, Visintin M, Bradbury A, Brancolini C, Verzillo V, et al. The neuronal microtubule-associated protein tau is a substrate for caspase-3 and an effector of apoptosis. J Neurochem (2000) 75:624-33. doi:10.1046/j.1471-4159.2000.0750624.x.
22. Chung CW, Song YH, Kim IK, Yoon WJ, Ryu BR, Jo DG, et al. Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis (2001) 8:162-72. doi:10.1006/nbdi.2000.0335.
23. Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, et al. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 100:10032-7. doi:10.1073/pnas.1630428100.
24. Horowitz PM, Patterson KR, Guillozet-Bongaarts AL, Reynolds MR, Carroll CA, Weintraub ST, et al. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer's disease. J Neurosci (2004) 24:7895-902. doi:10.1523/JNEUROSCI.1988-04.2004.
25. Lee MJ, Lee JH, Rubinsztein DC. Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol (2013) 105:49-59. doi:10.1016/j.pneurobio.2013.03.001.
26. Drubin D, Kobayashi S, Kellogg D, Kirschner M. Regulation of microtubule protein levels during cellular morphogenesis in nerve growth factor-treated PC12 cells. J Cell Biol (1988) 106:1583-91. doi:10.1083/jcb.106.5.1583.
27. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 25:402-5. doi:10.1038/78078.
28. Arai T, Guo JP, McGeer PL. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem (2005) 280:5145-53. doi:10.1074/jbc. M409234200.
29. Chow KM, Guan H, Hersh LB. Aminopeptidases do not directly degrade tau protein. Mol Neurodegener (2010) 5:48. doi:10.1186/1750-1326-5-48.
30. Nakamura K, Greenwood A, Binder L, Bigio EH, Denial S, Nicholson L, et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell (2012) 149:232-44. doi:10.1016/j.cell.2012.02.016.
31. Lim J, Balastik M, Lee TH, Nakamura K, Liou YC, Sun A, et al. Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest (2008) 118:1877-89. doi:10.1172/JCI34308.
32. Menzies FM, Hourez R, Imarisio S, Raspe M, Sadiq O, Chandraratna D, et al. Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy. Hum Mol Genet (2010) 19:4573-86. doi:10.1093/hmg/ddq385.
33. Yin X, Wright J, Wall T, Grammas P. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am J Pathol (2010) 176:1600-6. doi:10.2353/ajpath.2010.090406.
34. Gill JS, Pitts K, Rusnak FM, Owen WG, Windebank AJ. Thrombin induced inhibition of neurite outgrowth from dorsal root ganglion neurons. Brain Res (1998) 797:321-7. doi:10.1016/S0006-8993(98)00344-8.
35. Smirnova IV, Zhang SX, Citron BA, Arnold PM, FestoffBW. Thrombin is an extracellular signal that activates intracellular death protease pathways inducing apoptosis in model motor neurons. J Neurobiol (1998) 36:64-80. doi:10.1002/(SICI)1097-4695(199807)36:1<64::AID-NEU6>3.0.CO;2-8.
36. Turgeon VL, Lloyd ED, Wang S, FestoffBW, Houenou LJ. Thrombin perturbs neurite outgrowth and induces apoptotic cell death in enriched chick spinal motoneuron cultures through caspase activation. J Neurosci (1998) 18:6882-91.
37. Suo Z, Wu M, Citron BA, Palazzo RE, FestoffBW. Rapid tau aggregation and delayed hippocampal neuronal death induced by persistent thrombin signaling. J Biol Chem (2003) 278:37681-9. doi:10.1074/jbc. M301406200.
38. Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol (2006) 65:19-25. doi:10.1097/01.jnen.0000196133.74087.cb.
39. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. Proc Natl Acad Sci U S A (2007) 104:10252-7. doi:10.1073/pnas.0703676104.
40. De Luca A, De Falco M, Severino A, Campioni M, Santini D, Baldi F, et al. Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem (2003) 51:1279-84. doi:10.1177/002215540305101004.
41. Grau S, Baldi A, Bussani R, Tian X, Stefanescu R, Przybylski M, et al. Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci U S A (2005) 102:6021-6. doi:10.1073/pnas.0501823102.
42. Chien J, He X, Shridhar V. Identification of tubulins as substrates of serine protease HtrA1 by mixture-based oriented peptide library screening. J Cell Biochem (2009) 107:253-63. doi:10.1002/jcb.22121.
43. Chien J, Ota T, Aletti G, Shridhar R, Boccellino M, Quagliuolo L, et al. Serine protease HtrA1 associates with microtubules and inhibits cell migration. Mol Cell Biol (2009) 29:4177-87. doi:10.1128/MCB.00035-09.
44. Clausen T, Kaiser M, Huber R, Ehrmann M. HTRA proteases: regulated proteolysis in protein quality control. Nat Rev Mol Cell Biol (2011) 12:152-62. doi:10.1038/nrm3065.
45. Liu J, Liu MC, Wang KK. Calpain in the CNS: from synaptic function to neurotoxicity. Sci Signal (2008) 1:re1. doi:10.1126/stke.114re1.
46. Vosler PS, Brennan CS, Chen J. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol (2008) 38:78-100. doi:10.1007/s12035-008-8036-x.
47. Adamec E, Mohan P, Vonsattel JP, Nixon RA. Calpain activation in neurodegenerative diseases: confocal immunofluorescence study with antibodies specifically recognizing the active form of calpain 2. Acta Neuropathol (2002) 104:92-104. doi:10.1007/s00401-002-0528-6.
48. Ferreira A, Bigio EH. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med (2011) 17:676-85. doi:10.2119/molmed.2010.00220.
49. Olney JW, Wozniak DF, Farber NB. Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. Arch Neurol (1997) 54:1234-40. doi:10.1001/archneur.1997.00550220042012.
50. Wang Q, Yu S, Simonyi A, Sun GY, Sun AY. Kainic acid-mediated excitotoxicity as a model for neurodegeneration. Mol Neurobiol (2005) 31:3-16. doi:10.1385/MN:31:1-3:003.
51. D'Orsi B, Bonner H, Tuffy LP, Dussmann H, Woods I, Courtney MJ, et al. Calpains are downstream effectors of bax-dependent excitotoxic apoptosis. J Neurosci (2012) 32:1847-58. doi:10.1523/JNEUROSCI.2345-11.2012.
52. Park SY, Ferreira A. The generation of a 17 kDa neurotoxic fragment: an alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration. J Neurosci (2005) 25:5365-75. doi:10.1523/JNEUROSCI.1125-05.2005.
53. Reifert J, Hartung-Cranston D, Feinstein SC. Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive tau fragmentation without increased full-length tau phosphorylation. J Biol Chem (2011) 286:20797-811. doi:10.1074/jbc. M111.234674.
54. Reinecke JB, Devos SL, McGrath JP, Shepard AM, GoncharoffDK, Tait DN, et al. Implicating calpain in tau-mediated toxicity in vivo. PLoS ONE (2011) 6:e23865. doi:10.1371/journal.pone.0023865.
55. Cotman CW, Poon WW, Rissman RA, Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology. J Neuropathol Exp Neurol (2005) 64:104-12.
56. de Calignon A, Fox LM, Pitstick R, Carlson GA, Bacskai BJ, Spires-Jones TL, et al. Caspase activation precedes and leads to tangles. Nature (2010) 464:1201-4. doi:10.1038/nature08890.
57. Su JH, Zhao M, Anderson AJ, Srinivasan A, Cotman CW. Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res (2001) 898:350-7. doi:10.1016/S0006-8993(01)02018-2.
58. Guo H, Albrecht S, Bourdeau M, Petzke T, Bergeron C, Leblanc AC. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease. Am J Pathol (2004) 165:523-31. doi:10.1016/S0002-9440(10)63317-2.
59. Guillozet-Bongaarts AL, Garcia-Sierra F, Reynolds MR, Horowitz PM, Fu Y, Wang T, et al. Tau truncation during neurofibrillary tangle evolution in Alzheimer's disease. Neurobiol Aging (2005) 26:1015-22. doi:10.1016/j.neurobiolaging.2004.09.019.
60. Basurto-Islas G, Luna-Munoz J, Guillozet-Bongaarts AL, Binder LI, Mena R, Garcia-Sierra F. Accumulation of aspartic acid421-and glutamic acid391-cleaved tau in neurofibrillary tangles correlates with progression in Alzheimer disease. J Neuropathol Exp Neurol (2008) 67:470-83. doi:10.1097/NEN.0b013e31817275c7.
61. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 114:121-30. doi:10.1172/JCI20640.
62. Arnaud LT, Myeku N, Figueiredo-Pereira ME. Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. J Neurochem (2009) 110:328-42. doi:10.1111/j.1471-4159.2009.06142.x.
63. Metcalfe MJ, Huang Q, Figueiredo-Pereira ME. Coordination between proteasome impairment and caspase activation leading to TAU pathology: neuroprotection by cAMP. Cell Death Dis (2012) 3:e326. doi:10.1038/cddis.2012.70.
64. Hamano T, Gendron TF, Ko LW, Yen SH. Concentration-dependent effects of proteasomal inhibition on tau processing in a cellular model of tauopathy. Int J Clin Exp Pathol (2009) 2:561-73.
65. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini MG. Proteasomal degradation of tau protein. J Neurochem (2002) 83:176-85. doi:10.1046/j.1471-4159.2002.01137.x.
66. Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem (2005) 94:192-203. doi:10.1111/j.1471-4159.2005.03181.x.
67. Dickey CA, Dunmore J, Lu B, Wang JW, Lee WC, Kamal A, et al. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J (2006) 20:753-5.
68. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem (2000) 75:436-9. doi:10.1046/j.1471-4159.2000.0750436.x.
69. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem (2003) 85:115-22. doi:10.1046/j.1471-4159.2003.01642.x.
70. Wong ES, Tan JM, Soong WE, Hussein K, Nukina N, Dawson VL, et al. Autophagy-mediated clearance of aggresomes is not a universal phenomenon. Hum Mol Genet (2008) 17:2570-82. doi:10.1093/hmg/ddn157.
71. Grune T, Botzen D, Engels M, Voss P, Kaiser B, Jung T, et al. Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch Biochem Biophys (2010) 500:181-8. doi:10.1016/j.abb.2010.05.008.
72. Dolan PJ, Johnson GV. A caspase cleaved form of tau is preferentially degraded through the autophagy pathway. J Biol Chem (2010) 285:21978-87. doi:10.1074/jbc. M110.110940.
73. Zhang JY, Liu SJ, Li HL, Wang JZ. Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. J Neural Transm (2005) 112:547-55. doi:10.1007/s00702-004-0196-x.
74. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy (2011) 7:279-96. doi:10.4161/auto.7.3.14487.
75. Ivanov S, Roy CR. NDP52: the missing link between ubiquitinated bacteria and autophagy. Nat Immunol (2009) 10:1137-9. doi:10.1038/ni1109-1137.
76. von Muhlinen N, Akutsu M, Ravenhill BJ, Foeglein A, Bloor S, Rutherford TJ, et al. LC3C, bound selectively by a noncanonical LIR motif in NDP52, is required for antibacterial autophagy. Mol Cell (2012) 48:329-42. doi:10.1016/j.molcel.2012.08.024.
77. Watson RO, Manzanillo PS, Cox JS. Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway. Cell (2012) 150:803-15. doi:10.1016/j.cell.2012.06.040.
78. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev (2010) 90:1383-435. doi:10.1152/physrev.00030.2009.
79. Nixon RA, Wegiel J, Kumar A, Yu WH, PeterhoffC, Cataldo A, et al. Extensive involvement of autophagy in Alzheimer disease: an immuno-electron microscopy study. J Neuropathol Exp Neurol (2005) 64:113-22.
80. Yang DS, Kumar A, Stavrides P, Peterson J, PeterhoffCM, Pawlik M, et al. Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer's disease. Am J Pathol (2008) 173:665-81. doi:10.2353/ajpath.2008.071176.
81. Sanchez-Varo R, Trujillo-Estrada L, Sanchez-Mejias E, Torres M, Baglietto-Vargas D, Moreno-Gonzalez I, et al. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus. Acta Neuropathol (2012) 123:53-70. doi:10.1007/s00401-011-0896-x.
82. Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis (2011) 43:38-45. doi:10.1016/j.nbd.2011.01.021.
83. Nixon RA, Yang DS. Autophagy and neuronal cell death in neurological disorders. Cold Spring Harb Perspect Biol (2012) 4:a008839. doi:10.1101/cshperspect.a008839.
84. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain (2011) 134:258-77. doi:10.1093/brain/awq341.
85. Bi X, Zhou J, Lynch G. Lysosomal protease inhibitors induce meganeurites and tangle-like structures in entorhinohippocampal regions vulnerable to Alzheimer's disease. Exp Neurol (1999) 158:312-27. doi:10.1006/exnr.1999.7087.
86. Bi X, Haque TS, Zhou J, Skillman AG, Lin B, Lee CE, et al. Novel cathepsin D inhibitors block the formation of hyperphosphorylated tau fragments in hippocampus. J Neurochem (2000) 74:1469-77. doi:10.1046/j.1471-4159.2000.0741469.x.
87. Yang AJ, Chandswangbhuvana D, Margol L, Glabe CG. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Abeta1-42 pathogenesis. J Neurosci Res (1998) 52:691-8. doi:10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3.
88. Ditaranto K, Tekirian TL, Yang AJ. Lysosomal membrane damage in soluble Abeta-mediated cell death in Alzheimer's disease. Neurobiol Dis (2001) 8:19-31. doi:10.1006/nbdi.2000.0364.
89. Bednarski E, Lynch G. Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L. J Neurochem (1996) 67:1846-55. doi:10.1046/j.1471-4159.1996.67051846.x.
90. Johnson GV, Litersky JM, Whitaker JN. Proteolysis of microtubule-associated protein 2 and tubulin by cathepsin D. J Neurochem (1991) 57:1577-83. doi:10.1111/j.1471-4159.1991.tb06354.x.
91. Bendiske J, Bahr BA. Lysosomal activation is a compensatory response against protein accumulation and associated synaptopathogenesis-an approach for slowing Alzheimer disease? J Neuropathol Exp Neurol (2003) 62:451-63.
92. Hamano T, Gendron TF, Causevic E, Yen SH, Lin WL, Isidoro C, et al. Autophagic-lysosomal perturbation enhances tau aggregation in transfectants with induced wild-type tau expression. Eur J Neurosci (2008) 27:1119-30. doi:10.1111/j.1460-9568.2008.06084.x.
93. Khurana V, Elson-Schwab I, Fulga TA, Sharp KA, Loewen CA, Mulkearns E, et al. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet (2010) 6:e1001026. doi:10.1371/journal.pgen.1001026.
94. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E, Mandelkow EM, et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet (2009) 18:4153-70. doi:10.1093/hmg/ddp367.
95. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, et al. Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy (2012) 8:609-22. doi:10.4161/auto.19048.
96. Kruger U, Wang Y, Kumar S, Mandelkow EM. Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging (2012) 33:2291-305. doi:10.1016/j.neurobiolaging.2011.11.009.
97. Schaeffer V, Lavenir I, Ozcelik S, Tolnay M, Winkler DT, Goedert M. Stimulation of autophagy reduces neurodegeneration in a mouse model of human tauopathy. Brain (2012) 135:2169-77. doi:10.1093/brain/aws143.
98. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, et al. mTor regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell (2013) 12:370-80. doi:10.1111/acel.12057.
99. Inoue K, Rispoli J, Kaphzan H, Klann E, Chen EI, Kim J, et al. Macroautophagy deficiency mediates age-dependent neurodegeneration through a phospho-tau pathway. Mol Neurodegener (2012) 7:48. doi:10.1186/1750-1326-7-48.
100. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A, et al. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet (2004) 13:703-14. doi:10.1093/hmg/ddh083.
101. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron (1993) 10:1151-60. doi:10.1016/0896-6273(93)90063-W.
102. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem (2006) 281:10825-38. doi:10.1074/jbc. M512786200.
103. Dice JF. Chaperone-mediated autophagy. Autophagy (2007) 3:295-9.
104. Knaevelsrud H, Simonsen A. Fighting disease by selective autophagy of aggregate-prone proteins. FEBS Lett (2010) 584:2635-45. doi:10.1016/j.febslet.2010.04.041.
105. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem (2007) 282:24131-45. doi:10.1074/jbc. M702824200.
106. Dolan PJ, Jin YN, Hwang W, Johnson GV. Decreases in valosin-containing protein result in increased levels of tau phosphorylated at Ser262/356. FEBS Lett (2011) 585:3424-9. doi:10.1016/j.febslet.2011.09.032.
107. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett (2010) 584:1393-8. doi:10.1016/j.febslet.2009.12.047.
108. Tseng BP, Green KN, Chan JL, Blurton-Jones M, Laferla FM. Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2008) 29:1607-18. doi:10.1016/j.neurobiolaging.2007.04.014.